Gujarat Terce Laboratories (BOM:524314) EBIT : ₹-0.8 Mil (TTM As of Dec. 2023)

View and export this data going back to 1994. Start your Free Trial

What is Gujarat Terce Laboratories EBIT?

Gujarat Terce Laboratories's earnings before interest and taxes (EBIT) for the three months ended in Dec. 2023 was ₹8.4 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2023 was ₹-0.8 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Gujarat Terce Laboratories's annualized ROC % for the quarter that ended in Dec. 2023 was 13.37%. Gujarat Terce Laboratories's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was 46.80%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Gujarat Terce Laboratories's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -0.17%.

Gujarat Terce Laboratories EBIT Historical Data

The historical data trend for Gujarat Terce Laboratories's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gujarat Terce Laboratories EBIT Chart

Gujarat Terce Laboratories Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

EBIT

Get a 7-Day Free Trial

5.82

6.90

-21.87

10.80

-22.26

Gujarat Terce Laboratories Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EBIT	Get a 7-Day Free Trial															1.36	-3.06	-11.42	5.35	8.36

Competitive Comparison of Gujarat Terce Laboratories's EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Gujarat Terce Laboratories's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Gujarat Terce Laboratories's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Gujarat Terce Laboratories's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Gujarat Terce Laboratories's EV-to-EBIT falls into.

Gujarat Terce Laboratories EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹-0.8 Mil.

Gujarat Terce Laboratories (BOM:524314) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Gujarat Terce Laboratories's annualized ROC % for the quarter that ended in Dec. 2023 is calculated as:

	ROC % (Q: Dec. 2023 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Sep. 2023 )	+	Invested Capital (Q: Dec. 2023 ))	/ count )
=	30.248 * ( 1 - 0% )	/	( (226.292	+	0)	/ 1 )
=	30.248	/	226.292
=	13.37 %

where

	Invested Capital		(Q: Sep. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	254.613	-	37.078	-	( 0.893	-	max(0, 140.365	-	131.608	+	0.893	))
=	226.292

	Invested Capital		(Q: Dec. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	0	-	0	-	( 0	-	max(0, 0	-	0	+	0	))
=	0

Note: The Operating Income data used here is four times the quarterly (Dec. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

Gujarat Terce Laboratories's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Dec. 2023 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Sep. 2023		Q: Dec. 2023
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	33.432	/	( ( (38.128 + max(33.305, 0))	+	(0 + max(0, 0)) )	/	1 )
=	33.432	/	( ( 71.433	+	0 )	/	1 )
=	33.432	/	71.433
=	46.80 %

where Working Capital is:

	Working Capital		(Q: Sep. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(72.655	+	40.741	+	15.736)	-	(37.078	+	0	+	58.749)
=	33.305

	Working Capital		(Q: Dec. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	0)	-	(0	+	0	+	0)
=	0

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Gujarat Terce Laboratories's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Dec. 2023 )
	=	-0.775	/	458.811
	=	-0.17 %

Gujarat Terce Laboratories EBIT Related Terms

Thank you for viewing the detailed overview of Gujarat Terce Laboratories's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Gujarat Terce Laboratories (BOM:524314) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Gujarat Terce Laboratories Ltd (BOM:524314) » Definitions » EBIT

Traded in Other Exchanges

N/A

Address

Near Shivalik High-Street,, D/801 & 802,The First,, Behind Keshavbaug Party Plot,, Vastrapur,, Ahmedabad, GJ, IND, 380015

Website

https://www.gujaratterce.in

Gujarat Terce Laboratories Ltd is an India company having business in the medical and pharmaceutical preparations. It is engaged in the manufacturing of tablets, capsules, and syrup and injection. It offers branded as well as generic formulations covering different therapeutic areas such as antibiotics, respiratory, nutraceuticals, gastrointestinal, anti-fungal, and many more. Some of the main brands are Acolate, Tynol, DFS, Resplash , Aziter and others.

Gujarat Terce Laboratories (BOM:524314) Headlines

No Headlines